3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
25
Salivary Gland Neoplasms
2
Metastatic Castration-resistant Prostate Cancer
2
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Neoplasms
1
Neoplasm Metastasis
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Carcinoma, Intraductal, Noninfiltrating
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Cancer Female
1
Biochemically Recurrent Prostate Cancer
1
Interventions
Abiraterone Acetate
5
enzalutamide
4
abiraterone
3
Prednisone
3
apalutamide
2
Nivolumab
2
Docetaxel
2
pembrolizumab
1
niraparib
1
darolutamide
1
cabazitaxel
1
Pluvicto
1
Omeprazole
1
Ipilimumab
1
Drug Therapy
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms, Castration-Resistant
×
darolutamide
×
Clear all
NCT04157088
2023-08-04
DaroAcT
Bayer
Phase 2
Terminated
30 enrolled
25 charts